Market Closed -
Hong Kong S.E.
04:08:28 2024-05-24 am EDT
|
5-day change
|
1st Jan Change
|
11
HKD
|
0.00%
|
|
+3.19%
|
-10.57%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
8,845
|
6,776
|
6,129
|
-
|
-
|
Enterprise Value (EV)
1 |
8,845
|
6,776
|
5,582
|
6,129
|
6,129
|
P/E ratio
|
21.6
x
|
-65.8
x
|
-255
x
|
204
x
|
92.7
x
|
Yield
|
-
|
-
|
32.9%
|
33.1%
|
34.2%
|
Capitalization / Revenue
|
2.35
x
|
7.6
x
|
6.26
x
|
5.63
x
|
4.92
x
|
EV / Revenue
|
2.35
x
|
7.6
x
|
5.7
x
|
5.63
x
|
4.92
x
|
EV / EBITDA
|
14.4
x
|
-
|
34.2
x
|
29.9
x
|
-
|
EV / FCF
|
-49.3
x
|
-
|
47.1
x
|
29.3
x
|
18.7
x
|
FCF Yield
|
-2.03%
|
-
|
2.12%
|
3.42%
|
5.35%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
621,251
|
606,149
|
601,087
|
-
|
-
|
Reference price
2 |
14.24
|
11.18
|
10.20
|
10.20
|
10.20
|
Announcement Date
|
3/30/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
3,756
|
891.5
|
979.3
|
1,089
|
1,245
|
EBITDA
1 |
-
|
614.6
|
-
|
163
|
205
|
-
|
EBIT
1 |
-
|
458.6
|
-112.2
|
-7
|
56.5
|
114.5
|
Operating Margin
|
-
|
12.21%
|
-12.58%
|
-0.71%
|
5.19%
|
9.2%
|
Earnings before Tax (EBT)
1 |
-
|
443.4
|
-86.81
|
-28.05
|
38.64
|
80.09
|
Net income
1 |
380.9
|
377.3
|
-102.3
|
-25.31
|
30.56
|
66.62
|
Net margin
|
-
|
10.04%
|
-11.47%
|
-2.58%
|
2.8%
|
5.35%
|
EPS
2 |
38.21
|
0.6600
|
-0.1700
|
-0.0400
|
0.0500
|
0.1100
|
Free Cash Flow
1 |
-
|
-179.5
|
-
|
118.5
|
209.5
|
328
|
FCF margin
|
-
|
-4.78%
|
-
|
12.1%
|
19.23%
|
26.35%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
72.7%
|
102.2%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
685.63%
|
492.33%
|
Dividend per Share
2 |
-
|
-
|
-
|
3.350
|
3.380
|
3.490
|
Announcement Date
|
5/4/22
|
3/30/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
547
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-179
|
-
|
119
|
210
|
328
|
ROE (net income / shareholders' equity)
|
-
|
18.9%
|
-
|
-0.63%
|
1.53%
|
2.4%
|
ROA (Net income/ Total Assets)
|
-
|
10.2%
|
-
|
-0.9%
|
0.95%
|
3%
|
Assets
1 |
-
|
3,681
|
-
|
2,812
|
3,216
|
2,221
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
317
|
-
|
117
|
93.3
|
93.3
|
Capex / Sales
|
-
|
8.44%
|
-
|
11.91%
|
8.57%
|
7.5%
|
Announcement Date
|
5/4/22
|
3/30/23
|
3/25/24
|
-
|
-
|
-
|
Last Close Price
10.2
CNY Average target price
12.93
CNY Spread / Average Target +26.79% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.57% | 847M | | -23.07% | 8.1B | | +68.36% | 4.26B | | +1.88% | 2.57B | | -8.06% | 2.49B | | -41.95% | 2.39B | | -11.99% | 1.77B | | -21.18% | 1.53B | | +17.44% | 1.2B | | -43.89% | 1.18B |
Medical & Diagnostic Laboratories
|